Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
| Revenue (TTM) | $6.16B |
| Gross Profit (TTM) | $4.21B |
| EBITDA | $1.34B |
| Operating Margin | 14.00% |
| Return on Equity | 11.80% |
| Return on Assets | 5.27% |
| Revenue/Share (TTM) | $2.84 |
| Book Value | $2.49 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 2.22 |
| EV/Revenue | 2.567 |
| EV/EBITDA | 10.33 |
| Quarterly Earnings Growth (YoY) | 70.40% |
| Quarterly Revenue Growth (YoY) | 7.40% |
| Shares Outstanding | $420.79M |
| Float | $2.10B |
| % Insiders | 0.01% |
| % Institutions | 10.10% |
Volatility is currently expanding
SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Smith & Nephew PLC (LSE:SN) efforts to expand its surgical robotics platform and strengthen its orthopaedics pipeline received a vote of confidence from surgeons at a recent investor event, according to analysts at JPMorgan. Analyst Veronika Dubajova said discussions at the medical technology group's Expert Surgeon Insights event in London left her incrementally more positive on the prospects for CORI, Smith & Nephew's robotic-assisted surgery platform.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3
Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SNN and any ticker you trade — then tracks every position and per-strategy win rate.
